PALO ALTO, Calif., Sept. 15, 2020 /PRNewswire/ --
- Integration of Dual Energy CT (DECT) images in the Eclipse
planning process reduces range uncertainty and helps clinicians'
spare healthy tissue.
- Graphics Processing Unit (GPU) accelerates the speed of
Monte Carlo proton dose
calculation and improves efficiency in treatment planning.
Varian (NYSE: VAR) today announced it has received FDA 510(k)
clearance for its Eclipse v16.1 treatment planning software for
proton therapy. Proton therapy is the most sophisticated
radiotherapy technology available today, using protons, accelerated
to about two-thirds the speed of light, or more than 100,000 miles
per second, to destroy cancer cells, while minimizing exposure to
nearby healthy tissue.
With the release of Eclipse v16.1 treatment planning software,
Varian introduces intelligent treatment planning features,
leveraging Siemens Healthineers' SOMATOM DECT diagnostic
imager with its dual x-ray energies capability. This new
capability not only enhances visibility of soft tissue, but also
provides more accurate information about tissue density allowing
dosimetrists to plan more precisely. This feature was validated
through a clinical collaboration with the Roberts Proton Therapy
Center at the University of
Pennsylvania1. Also included in Eclipse
v16.1 is the first clinical release of GPU Monte Carlo proton dose
calculation technology, that was evaluated in partnership with the
Emory Proton Therapy Center in Atlanta,
Georgia. This technology enables clinicians to accelerate
calculation speed and improve overall treatment planning
"As a leader in proton therapy, Varian's goal is to drive the
next evolution of proton treatment planning by providing
intelligent tools designed to improve plan quality, accelerate
speed of dose calculations, and provide new levels of accuracy,"
said Kolleen Kennedy, President,
Proton Solutions & Chief Growth Officer, Varian. "With the
launch of Eclipse v16.1 we continue to build on our strong
foundation, providing the most sophisticated proton therapy
planning solutions to our clinical users across the globe."
Eclipse v16.1 has received FDA 510(k) clearance. For more
information on Eclipse v16.1, visit www.varian.com/eclipse
1Presented at AAPM 2020, author: Teo et al, "Proton
dose calculation with Dual Energy CT using scripting"
At Varian, we envision a world without
fear of cancer. For more than 70 years, we have developed, built
and delivered innovative cancer care technologies and solutions for
our clinical partners around the globe to help them treat millions
of patients each year. With an Intelligent Cancer Care approach, we
are harnessing advanced technologies like artificial intelligence,
machine learning and data analytics to enhance cancer treatment and
expand access to care. Our 10,000 employees across 70 locations
keep the patient and our clinical partners at the center of our
thinking as we power new victories in cancer care. Because, for
cancer patients everywhere, their fight is our fight. For more
information, visit http://www.varian.com and follow
@VarianMedSys on Twitter.
Sr. Director, Global Brand and Marketing
1 (650) 424-5208
Investor Relations Contact
Vice President, Investor Relations
+1 (650) 424-5631